And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is a bit different this time around, since we will be headed toward an out-of-town venue in preparation for a panel appearance (and this means we will have a substitute for us on Monday). And what about you? There is still time to enjoy the autumn, so perhaps a drive in the country is in order. You could also look ahead to the upcoming holiday season and decide where to go, whom to see, and what to do. Or you could engage in a new sport and ponder the meaning of quid pro quo. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon.

Sen. Cory Booker (D-N.J.) and Sen. Bernie Sanders (I-Vt.) introduced a bill that would create a new federal agency focused on controlling the costs of prescription drugs, The Hill reports. The Prescription Drug Affordability and Access Act would form the Bureau of Prescription Drug Affordability and Access. One of the main tenets of the proposal is that if a drug company did not comply with the regulations, it would void exclusivity protections, allowing other companies to produce generic copies of a drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy